The CCDC22 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the MES-OV human ovarian carcinoma cell line. This product provides a genetically heterogeneous pool of MES-OV cells with targeted disruption of CCDC22, enabling loss-of-function studies in an ovarian epithelial cancer context. The polyclonal format preserves cellular diversity while ensuring robust gene ablation across the population.
MES-OV is a well-characterized ovarian carcinoma cell line that models epithelial ovarian cancer, the most common and lethal gynecological malignancy. Originating from a patient tumor, these cells retain key oncogenic signaling and phenotypic traits, including altered adhesion, proliferation, and metabolic reprogramming, making them widely used in tumor biology and drug response research.
CCDC22 encodes a core subunit of the CCC complex, which regulates endosomal receptor recycling and copper homeostasis. Within this complex, CCDC22 interacts with COMMD1-10, CCDC93, ATP7A, and clathrin on recycling endosomes, facilitating ATP7A surface expression and copper export. Knockout of CCDC22 disrupts CCC complex formation, impairing endosomal trafficking and reducing ATP7A localization, leading to defective copper transport. This also affects recycling of various surface receptors, linking CCDC22 to broader endosomal sorting processes.
In MES-OV ovarian cancer cells, CCDC22 knockout enables dissection of how endosomal recycling and copper homeostasis influence tumor behavior. Copper is a cofactor for enzymes involved in angiogenesis and proliferation, and its dysregulation is linked to cancer progression. This model allows investigation of CCC complex-mediated pathways in copper-dependent oncogenesis and response to copper-modulating therapies. Moreover, as CCDC22 mutations cause X-linked syndromic intellectual disability and retinitis pigmentosa, this line also supports cross-tissue studies of CCC-related neurodevelopmental and retinal disorders.
The polyclonal knockout population is suitable for ATP7A immunofluorescence, copper uptake assays, western blotting, RT-qPCR of copper-responsive genes, and flow cytometry for surface receptor recycling. Applications include studies of copper metabolism in cancer, endosomal trafficking disorders, ovarian cancer cell biology, and disease modeling. For further information, contact Ascent Research.
